Fewer than 10% of individuals that would benefit from weight-loss injections like Wegovy have access to them, caution the global health agency as it publishes its initial advice on the drugs.
Given in excess of 1,000,000,000 people worldwide currently classified as obese, it is advocating for more widespread and fairer access to GLP-1 medication.
According to estimates, over two billion could be living with obesity by 2030 if no action is taken.
"The latest guidelines affirms that obesity is a chronic disease that can be treated with comprehensive and lifelong support," stated the agency's head Tedros Adhanom Ghebreyesus.
Substantial prices, insufficient output, and supply-chain constraints are key barriers to broad access to the jabs that can help people shift significant body mass, explains the agency.
Weight-Loss Drug Scarcity
Despite the present most favorable case, the production of GLP-1 therapies might only reach approximately 100 million people – fewer than 10% of eligible patients, according to the health organization.
The recommendation urges governments and firms to expand availability, by strategies including voluntary licensing.
A patent on semaglutide – the primary ingredient of the drug Wegovy – is scheduled to end in multiple countries in 2026.
The Way Obesity Jabs Function
The injections replicate a biological compound to reduce digestion speed, suppress the appetite and increase feelings of fullness so users reduce food intake.
Individuals commonly see weight reduction in the initial weeks of commencing the once-weekly jabs.
Research suggests users may see weight return a year later of discontinuing the medication, as their normal appetite come back.
Being overweight or obese raises your likelihood for contracting diseases, such as diabetes, heart disease, brain attack, and specific cancers.
Excess weight impacts individuals in all nations and was associated with over three and a half million deaths worldwide in 2024, per the health agency.
